Skip to main content
Rationale and design of the Kidney Precision Medicine Project.
Kidney international
  • Ian H de Boer
  • Charles E Alpers
  • Evren U Azeloglu
  • Ulysses G J Balis
  • Jonathan M Barasch
  • Laura Barisoni
  • Kristina N Blank
  • Andrew S Bomback
  • Keith Brown
  • Pierre C Dagher
  • Ashveena L Dighe
  • Michael T Eadon
  • Tarek M El-Achkar
  • Joseph P Gaut
  • Nir Hacohen
  • Yongqun He
  • Jeffrey B Hodgin
  • Sanjay Jain
  • John A Kellum
  • Krzysztof Kiryluk
  • Richard Knight
  • Zoltan G Laszik
  • Chrysta Lienczewski
  • Laura H Mariani
  • Robyn L McClelland
  • Steven Menez
  • Dennis G Moledina
  • Sean D Mooney
  • John F O'Toole
  • Paul M Palevsky
  • Chirag R Parikh
  • Emilio D Poggio
  • Sylvia E Rosas
  • Matthew R Rosengart
  • Minnie M Sarwal
  • Jennifer A Schaub
  • John R Sedor
  • Kumar Sharma
  • Becky Steck
  • Robert D Toto
  • Olga G Troyanskaya
  • Katherine Tuttle, Providence
  • Miguel A Vazquez
  • Sushrut S Waikar
  • Kayleen Williams
  • Francis Perry Wilson
  • Kun Zhang
  • Ravi Iyengar
  • Matthias Kretzler
  • Jonathan Himmelfarb
  • Kidney Precision Medicine Project
Document Type
Publication Date
  • washington,
  • spokane,
  • pshmc

Chronic kidney disease (CKD) and acute kidney injury (AKI) are common, heterogeneous, and morbid diseases. Mechanistic characterization of CKD and AKI in patients may facilitate a precision-medicine approach to prevention, diagnosis, and treatment. The Kidney Precision Medicine Project aims to ethically and safely obtain kidney biopsies from participants with CKD or AKI, create a reference kidney atlas, and characterize disease subgroups to stratify patients based on molecular features of disease, clinical characteristics, and associated outcomes. An additional aim is to identify critical cells, pathways, and targets for novel therapies and preventive strategies. This project is a multicenter prospective cohort study of adults with CKD or AKI who undergo a protocol kidney biopsy for research purposes. This investigation focuses on kidney diseases that are most prevalent and therefore substantially burden the public health, including CKD attributed to diabetes or hypertension and AKI attributed to ischemic and toxic injuries. Reference kidney tissues (for example, living-donor kidney biopsies) will also be evaluated. Traditional and digital pathology will be combined with transcriptomic, proteomic, and metabolomic analysis of the kidney tissue as well as deep clinical phenotyping for supervised and unsupervised subgroup analysis and systems biology analysis. Participants will be followed prospectively for 10 years to ascertain clinical outcomes. Cell types, locations, and functions will be characterized in health and disease in an open, searchable, online kidney tissue atlas. All data from the Kidney Precision Medicine Project will be made readily available for broad use by scientists, clinicians, and patients.

Clinical Institute
Kidney & Diabetes
Citation Information
Ian H de Boer, Charles E Alpers, Evren U Azeloglu, Ulysses G J Balis, et al.. "Rationale and design of the Kidney Precision Medicine Project." Kidney international (2021)
Available at: